Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.75 |
| ▸ | BRD4 | O60885 | 4/20 | 0.75 |
| ▸ | BRD2 | P25440 | 1/20 | 0.75 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.73 |
| ▸ | PRKACA | P17612 | 2/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.73 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.73 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.73 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.73 |
| ▸ | PRKCG | P05129 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167691 | 0.90 | MAPK14 (0.81) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL21797183 | 0.90 | MAPK14 (0.83) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL1641005 | 0.90 | MAPK14 (0.81) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL24170595 | 0.89 | MAPK14 (0.81) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL24170876 | 0.89 | MAPK14 (1.00) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL27441160 | 0.88 | MAPK14 (1.00) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL24170875 | 0.88 | MAPK14 (0.80) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL24170872 | 0.87 | MAPK14 (0.78) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL22730369 | 0.86 | MAPK14 (0.85) | MAPK14BRDTBRD4BRD2BRD3 | |
| SCHEMBL6581980 | 0.86 | MAPK14 (1.00) | MAPK14BRDTBRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1177299-A | Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine | SMITHKLINE BEECHAM CORP (US) | 1998-03-25 | — | — | CN | claimed |
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| CN-102686580-A | Imidazole derivatives as casein kinase inhibitors | PFIZER | 2012-09-19 | — | — | CN | disclosed |
| WO-2011051858-A1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050261318-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | MAPK14 136/4885BRDT 649/4885BRD4 1018/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | MAPK14 132/4885BRDT 618/4885BRD4 1032/4885 |
| US-20050261318-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | MAPK14 132/4885BRDT 618/4885BRD4 1032/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | MAPK14 421/4885BRDT 1144/4885BRD4 1050/4885 |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | MAPK14 169/4885BRDT 829/4885BRD4 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.